10-Q

                  UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	    Washington, D.C. 20549

	          FORM 10-Q

(Mark One)
  X   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For quarterly period ended:  March 31, 2017

      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from           to
                              ___________  ___________

Commission File Number:             0-6658

            SCIENTIFIC INDUSTRIES, INC.
______________________________________________________
(Exact name of registrant as specified in its charter)

       Delaware         		    04-2217279
____________________________    _________________________________
(State or other jurisdiction	(IRS Employer Identification No.)
 of incorporation or
 organization)

80 Orville Drive, Suite 102, Bohemia, New York        11716
______________________________________________     __________
  (Address of principal executive offices)	   (Zip Code)

                    (631)567-4700
____________________________________________________
(Registrant's telephone number, including area code)

                   Not Applicable
_____________________________________________________________________
(Former name, former address and former fiscal year, if changed since
last report)

Indicate by check whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.   Yes   X   No      .

Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company.  See the definitions of "large accelerated filer,"
"accelerated filer" and (smaller reporting company) in Rule 12b-2 of the
Exchange Act.

Large accelerated filer      		Accelerated Filer

Non-accelerated filer        		Smaller reporting company   X
    (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).
                                                          Yes    X No

The number of shares outstanding of the issuer's common stock par value,
$0.05 per share, as of May 1, 2017 was 1,494,112 shares.






                       TABLE OF CONTENTS



							Page
                                                        ____

Condensed Consolidated Balance Sheets	     	         1

Condensed Consolidated Statements of Operations		 2

Condensed Consolidated Statements of Comprehensive
Income (Loss)						 3

Condensed Consolidated Statements of Cash Flows		 4

Notes to Condensed Consolidated Financial Statements	 5

ITEM 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF
        OPERATIONS	                                12

ITEM 4	CONTROLS AND PROCEDURES				16

PART II - OTHER INFORMATION

ITEM 6	EXHIBITS AND REPORTS ON FORM 8-K	        16

SIGNATURE 						17

EXHIBITS						18












PART I-FINANCIAL INFORMATION
Item 1.  Financial Statements


SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
                 ASSETS
                                       March 31,   June 30,
                                           2017         2016
                                       (Unaudited)
                                        ___________  __________
Current Assets:
  Cash and cash equivalents		$1,211,300   $ 1,245,000
  Investment securities			   294,000	 290,100
  Trade accounts receivable, net	 1,327,700     1,231,900
  Inventories				 2,205,900     2,412,100
  Prepaid expenses and other current
   assets		 		    73,100	  47,200
  Deferred taxes			   141,000	 140,600
					__________   ___________
    Total current assets		 5,253,000     5,366,900

Property and equipment at cost, net	   212,900	 251,100

Intangible assets, net  		   690,200       897,600

Goodwill				   705,300	 705,300

Other assets				    52,500	  52,500

Deferred taxes				   284,200	 275,900
                                        __________    __________
    Total assets                        $7,198,000    $7,549,300
                                        ==========    ==========
	LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
  Accounts payable			$  343,100    $  342,400
  Customer advances			   107,900	    -
  Notes payable, current portion	     6,600  	   6,400
  Accrued expenses, current
    portion		   		   532,000	 849,700
  Contingent consideration, current
    portion			   	    16,000	 136,500
					__________    __________
      Total current liabilities		 1,005,600     1,335,000

Notes payable, less current portion	     7,500	  12,500
Accrued expenses, less current portion	    60,000	  60,000
Contingent consideration payable,
  less current portion	    		   164,200	 209,800
					__________   ___________
       Total liabilities		 1,237,300     1,617,300
					__________   ___________
Shareholders' equity:
  Common stock, $.05 par value; authorized 7,000,000 shares;
    1,513,914 and 1,508,914 issued
      and outstanding at March 31, 2017
       and June 30, 2016	            75,700	  75,400
  Additional paid-in capital		 2,515,000     2,498,500
  Accumulated other comprehensive
   income (loss)		   	(    4,700)	     900
  Retained earnings                      3,427,100     3,409,600
					___________   __________
                                         6,013,100     5,984,400
  Less common stock held in treasury, at cost,
   19,802 shares                            52,400	  52,400
					___________   __________
      Total shareholders' equity         5,960,700     5,932,000
                                        ___________   __________
      Total liabilities and
         shareholders' equity           $7,198,000    $7,549,300
 					==========    ==========


See notes to unaudited condensed consolidated financial statements
                                  1




       SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

                          For the Three Month	  For the Nine Month
                             Periods Ended          Periods Ended
                                 March 31,               March 31,
                         ______________________ _____________________
                             2017      2016         2017       2016
                         ______________________ _____________________
Revenues                 $1,910,900  $1,674,300 $6,153,800  $5,146,900
Cost of revenues          1,054,800     993,100  3,833,200   3,032,900
                         __________  __________ __________  __________
Gross profit                856,100     681,200  2,320,600   2,114,000
                         __________  __________ __________  __________
Operating expenses:
 General & administrative   435,100     426,700  1,256,700   1,230,500
 Selling                    223,900     196,200    664,800     590,400
 Research & development     114,100      93,400    334,500     263,000
                         __________  __________ __________  __________
  Total operating
  expenses  		    773,100     716,300  2,256,000   2,083,900
                         __________  __________ __________  __________
Income (loss) from
 operations   		     83,000    ( 35,100)    64,600      30,100
                         __________  __________ __________  __________
Other income (expense):
 Investment income	      1,100         300     10,100	 5,700
 Other			       -            200	     5,700   (	 3,000)
 Interest expense	  (   1,200)   ( 13,700) (   2,200)  (  35,900)
                         __________  __________  _________  __________
  Total other income,
  (expense) net		  (     100)   ( 13,200)    13,600   (  33,200)
                         __________  __________  _________  __________
 Income (loss) before
 income taxes (benefit)      82,900    ( 48,300)    78,200   (   3,100)
                         __________  __________  _________  __________
Income tax expense (benefit):
  Current		     38,900       2,200     23,400      43,100
  Deferred		 (   21,600)   ( 13,600)  (  7,400)  (  43,600)
                         __________  __________  _________  __________
Total income tax
  expense (benefit)	     17,300    ( 11,400)    16,000   (     500)
                         __________  __________  _________  __________
Net income (loss)         $  65,600   ($ 36,900)  $ 62,200   ($  2,600)
                         ==========  ==========  =========  ==========

Basic earnings (loss) per common
 share	                    $  .04     ($  .02)   $  .04     ($ .00)
Diluted earnings (loss) per common
 share  		    $  .04     ($  .02)	  $  .04     ($ .00)

Cash dividends declared
 per common share	    $  .03  	$   -	  $  .03      $   -

See notes to unaudited condensed consolidated financial statements


                                         2





             SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(UNAUDITED)




		              For the Three Month    For the Nine Month
                                 Periods Ended          Periods Ended
                                    March 31,              March 31,
                              ____________________   ______________________
                                 2017      2016         2017       2016
                              ____________________   ______________________
Net income (loss)	      $ 65,600  ($ 36,900)   $  62,200  ($   2,600)

Other comprehensive income (loss):
  Unrealized holding gain (loss)
  arising during period,
  net of tax			 1,300      3,000   (    5,600) (    1,900)
                              ________  _________   __________  __________
Comprehensive income (loss)   $ 66,900  ($ 33,900)   $  56,600  ($   4,500)
                              ========  =========   ==========  ==========



































See notes to unaudited condensed consolidated financial statements


                               3




     SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

                                       For the Nine Month Periods Ended
                                        March 31, 2017  March 31, 2016
                                        ______________  ______________
Operating activities:
  Net Income (loss)			  $  62,200	($   2,600)
                                          _________     ___________
  Adjustments to reconcile net income (loss)
   to net cash provided by (used in) operating activities:
      Gain on sale of investments        (    3,200) 	      -
      Loss on asset disposal		       -	     2,700
      Depreciation and amortization	    276,500	   319,100
      Deferred income tax expense	  (   7,400)	 (  43,600)
 Stock-based compensation		      1,300	    11,200
	 Changes in operating assets and liabilities:
	    Accounts receivable		  (  95,800)	   364,600
         Inventories			    206,200	(1,461,200)
         Prepaid expenses and other current
          assets  			  (  25,900)	    13,800
         Accounts payable                       700	   194,700
         Customer advances		    107,900	   191,400
         Accrued expenses		  ( 317,700)	   195,000
         			          __________	__________
      Total adjustments	        	    142,600 	(  212,300)
					  __________    __________
      Net cash provided by (used in)
       operating activities		   204,800	(  214,900)
                                          __________    __________
Investing activities:
  Redemption of investment securities,
    available-for-sale			    11,100           -
  Purchase of investment securities,
    available-for-sale			(   18,700)	(   2,700)
  Capital expenditures			(   18,200)	(  45,100)
  Purchase of intangible assets		(   12,800)	(   7,400)
                                        ___________     __________
      Net cash used in investing
       activities			(   38,600)	(  55,200)
                                        ___________     __________
Financing activities:
 Line of credit proceeds		   250,000	  970,000
 Line of credit repayments		(  250,000) 	     -
 Cash dividend declared and paid        (   44,500)          -
 Payments of contingent consideration	(  166,100)    (  100,900)
 Proceeds from exercise of stock options    15,500           -
 Principal payments on note payable     (    4,800)          -
                                        ___________    ___________
      Net cash provided by (used in)
       financing activities             (  199,900)      869,100
                                        ___________    ___________
Net increase (decrease) in cash and cash
 equivalents				(   33,700)	 599,000
Cash and cash equivalents, beginning
  of year	                         1,245,000       482,000
                                        ___________   ___________
Cash and cash equivalents, end
  of period			        $1,211,300    $1,081,000
                                        ===========   ===========
Supplemental disclosures:
Cash paid during the period for:
 Income taxes				$  213,500    $   35,500
 Interest				     2,200	  27,200

See notes to unaudited condensed consolidated financial statements

                               4





SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


General:  The accompanying unaudited interim condensed consolidated
financial statements are prepared pursuant to the Securities
and Exchange Commission?s rules and regulations for reporting
on Form 10-Q. Accordingly, certain information and footnotes
required by accounting principles generally accepted in the
United States for complete financial statements are not
included herein. The Company believes all adjustments
necessary for a fair presentation of these interim statements
have been included and that they are of a normal and
recurring nature.  These interim statements should be read in
conjunction with the Company's financial statements and notes
thereto, included in its Annual Report on Form 10-K, for the
fiscal year ended June 30, 2016.  The results for the three
and nine months ended March 31, 2017, are not necessarily an
indication of the results for the full fiscal year ending
June 30, 2017.

1.	Summary of significant accounting policies:

	Principles of consolidation:

The accompanying consolidated financial statements include the
accounts of Scientific Industries, Inc. ("Scientific"), a Delaware
corporation, Altamira Instruments, Inc.("Altamira"), a wholly-owned
subsidiary and Delaware corporation, Scientific Packaging Industries,
Inc. (an inactive wholly-owned subsidiary and New York corporation)
and Scientific Bioprocessing, Inc. ("SBI"), a wholly-owned subsidiary
and Delaware corporation.  All are collectively referred to as the
"Company".  All material intercompany balances and transactions have
been eliminated.

2.	Recent Accounting Pronouncements:

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and
Other, (Topic 350): Simplifying the Test for Goodwill Impairment, which is
intended to simplify the subsequent measurement and impairment of goodwill.
The ASU simplifies the complexity of evaluating goodwill for impairment by
eliminating the second step of the impairment test, which compares the
implied fair value of a reporting unit's goodwill to the carrying amount of
that goodwill. Instead, the ASU requires entities to compare the fair value
of a reporting unit to its carrying amount in order to determine the amount
of goodwill impairment recognized. ASU No. 2017-04 is effective for fiscal
years and interim periods within those years beginning after December 15,
2019. Early adoption of all the amendments for ASU 2017-04 is permitted.
Amendments must be applied prospectively. The Company is in process of
assessing the impact of the adoption of ASU No. 2017-04 on its financial
position, results of operations and cash flows.

In February 2016, the FASB issued authoritative guidance that requires
lessees to account for most leases on their balance sheets with the
liability being equal to the present value of the lease payments.  The
right-of-use asset will be based on the lease liability adjusted for certain
costs such as direct costs.  Lease expense will be recognized similar to
current accounting guidance with operating leases resulting in a straight-
line expense and financing leases resulting in a front-loaded expense
similar to the current accounting for capital leases.  This guidance becomes
effective for the Company's fiscal 2020 first quarter, with early adoption
permitted.
                                5
  


This guidance must be adopted using a modified retrospective transition
approach for leases that exist or are entered into after the beginning of
the earliest comparative period in the financial statements, and provides
for certain practical expedients.  The Company is currently evaluating the
timing, impact and method of applying this guidance on its consolidated
financial statements.

3.  Segment Information and Concentrations:

The Company views its operations as three segments:  the manufacture and
marketing of standard benchtop laboratory equipment for research in
university, hospital and industrial laboratories sold primarily through
laboratory equipment distributors ("Benchtop Laboratory Equipment"),
the manufacture and marketing of custom-made catalyst research instruments
for universities, government laboratories, and chemical and petrochemical
companies sold on a direct basis ("Catalyst Research Instruments") and the
marketing and production of bioprocessing systems for laboratory research
in the biotechnology industry sold directly to customers and through
distributors ("Bioprocessing Systems").


Segment information is reported as follows (foreign sales are principally
to customers in Europe and Asia):


               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ ___________

Three months ended March 31, 2017:

 Revenues	$1,410,800 $  359,800   $  140,300 $    -    $1,910,900
 Foreign Sales	   611,400     37,100         -	        -	648,500
 Income(Loss)from
    Operations      88,900 (   82,400)      76,500	-        83,000
 Assets     	 4,170,900  1,822,200      485,700   719,200  7,198,000
 Long-Lived Asset
    Expenditures     4,600       -           7,000      -      	 11,600
 Depreciation and
    Amortization    73,500      1,600       12,000      -        87,100



               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ ___________

Three months ended March 31, 2016:

 Revenues       $1,279,300 $  364,900   $   30,100 $    -     $1,674,300
 Foreign Sales	   597,300     25,900         -	        -	 623,200
 Income(Loss)from
    Operations       2,800      5,500 (    29,600)  ( 13,800) (   35,100)
 Assets     	 4,358,700  2,898,400      746,200   595,000   8,598,300
 Long-Lived Asset
    Expenditures    31,500      3,200        3,700      -         38,400
 Depreciation and
    Amortization    74,800      9,000       24,500      -        108,300




                                        6




Approximately 54% and 50% of net sales of benchtop laboratory equipment
for the three month periods ended March 31, 2017 and 2016, respectively,
were derived from the Company's main product, the Vortex-Genie 2 mixer,
excluding accessories.

Approximately 21% and 22% of total benchtop laboratory equipment sales
were derived from the Torbal Scales Division for the three months ended
March 31, 2017 and 2016, respectively.

Two benchtop laboratory equipment customers accounted for approximately
15% and 19% of the segment's net sales for the three month periods ended
March 31, 2017 and 2016 (11% and 15% of total revenues, respectively,
for the periods).

Sales of catalyst research instruments are generally pursuant to large
orders averaging more than $100,000 per order to a limited numbers of
customers.  Sales to two customers in the three months ended March 31,
2017 and two different customers in the three months ended March 31,
2016, accounted respectively for 76% and 86% of the segment?s net
sales for each of the periods (14% and 19% of total revenues,
respectively, for the periods).


               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ __________
Nine months ended March 31, 2017:

 Revenues	$4,334,400  $1,629,400  $  190,000 $    -    $6,153,800
 Foreign Sales	 1,924,400      52,200        -	        -     1,976,600
 Income(Loss)from
    Operations     252,900  (  197,400)      9,100	-        64,600
 Assets     	 4,170,900   1,822,200     485,700   719,200  7,198,000
 Long-Lived Asset
    Expenditures    18,200        -         12,800      -        31,000
 Depreciation and
    Amortization   226,900      12,700      37,000      -       276,600




               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ __________
Nine months ended March 31, 2016:

 Revenues	$4,125,900  $  932,300  $   88,700 $    -    $5,146,900
 Foreign Sales	 1,960,700     139,200        -         -     2,099,900
 Income(Loss)from
    Operations     245,200  (   86,700) (   92,500) ( 35,900)    30,100
 Assets     	 4,358,700   2,898,400     746,200   595,000  8,598,300
 Long-Lived Asset
    Expenditures    39,900       3,200       9,400      -        52,500
 Depreciation and
    Amortization   222,800      22,900      73,400      -       319,100



Approximately 53% and 50% of net sales of benchtop laboratory equipment
for the nine month periods ended March 31, 2017 and 2016,respectively,
were derived from sales of the Company's main product, the Vortex-Genie 2
mixer, excluding accessories.
                                  7




Approximately 23% and 21% of total benchtop laboratory equipment sales
for the nine months ended March 31, 2017 and 2016, respectively, were
derived from sales of the Torbal Scales Division.

Two benchtop laboratory equipment customers, accounted for approximately
11% and 15% of the segment?s net sales (8% and 12% of total revenues)
for the nine month periods ended March 31, 2017 and 2016, respectively.

Sales of catalyst research instruments to four customers in the nine
months ended March 31, 2017 and to four other customers in the nine
months ended March 31, 2016 accounted for approximately 92% and 87% of
that segment's net sales (24% and 16% of total revenues) for the
respective nine month periods.

The Company's foreign sales are principally made to customers in Europe
and Asia. The Company also has an arrangement with a supplier for
annual minimum purchase commitments through February 2020 which the
Company has already met for the current year.

4.	Fair Value of Financial Instruments:

The FASB defines the fair value of financial instruments as the amount
that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement
date.  Fair value measurements do not include transaction costs.



The accounting guidance also expands the disclosure requirements
concerning fair value and establishes a fair value hierarchy of
valuation inputs.  The hierarchy prioritizes the inputs into three
levels based on the extent to which inputs used in measuring fair
value are observable in the market.  Each fair value measurement is
reported in one of the three levels, which is determined by the
lowest level input that is significant to the fair value measurement
in its entirety.  These levels are described below:

Level 1	Inputs that are based upon unadjusted quoted prices for
        identical instruments traded in active markets.

Level 2	Quoted prices in markets that are not considered to be active
        or financial instruments for which all significant inputs are
        observable, either directly or indirectly.

Level 3	Prices or valuations that require inputs that are both
        significant to the fair value measurement and unobservable.

The following tables set forth by level within the fair value hierarchy
the Company's financial assets and liabilities that were accounted for
at fair value on a recurring basis at March 31, 2017 and June 30, 2016
according to the valuation techniques the Company used to determine
their fair values:


                                    Fair Value Measurements Using Inputs
                                                Considered as

                            Fair Value at
                            March 31, 2017   Level 1    Level 2  Level 3
                            ______________  __________ _______  ________
Assets:

Cash and cash equivalents	$1,211,300  $1,211,300  $  -    $  -
Available for sale securities  	   294,000     294,000     -       -
Total				$1,505,300  $1,505,300  $  -    $  -

Liabilities:

Contingent consideration	$  180,200  $    -      $  -   	$180,200



                                       8




                                    Fair Value Measurements Using Inputs
                                                Considered as

                            Fair Value at
                            June 30, 2016   Level 1    Level 2  Level 3
                            ______________  __________ _______  ________
Assets:

Cash and cash equivalents	$1,245,000  $1,245,000  $  -    $  -
Available for sale securities      290,100     290,100     -       -
                                __________  __________  _______ ________
Total			        $1,535,100  $1,535,100  $  -    $  -
                                ==========  ==========  ======= ========
Liabilities:

Contingent consideration        $  346,300  $    -      $  -   	$346,300
                                ==========  ==========  ======= ========

The following table sets forth an analysis of changes during the nine
months ended March 31, 2017, Level 3 financial liabilities of the
Company:

	Beginning balance, June 30, 2016		$346,300
	Payments					(166,100)
                                                        _________
	Ending Balance, March 31, 2017   	        $180,200
                                                        =========

Investments in marketable securities classified as available-for-sale
by security type at March 31, 2017 and June 30, 2016 consisted of the
following:

  							    Unrealized
                                               	    Fair   Holding Gain
                                        Cost        Value     (Loss)
	                           ____________  _________ ____________
At March 31, 2017:

     Available for sale:
     Equity securities		      $  37,000	  $  49,500  $  12,500
     Mutual funds		        261,700	    244,500 (   17,200)
                                      _________   _________ ___________
                                      $ 298,700   $ 294,000 ($   4,700)
                                      =========   ========= ===========

  							    Unrealized
                                               	    Fair   Holding Gain
                                        Cost        Value     (Loss)
	                           ____________  _________ ____________
At June 30, 2016:

        Available for sale:
        Equity securities           $   29,300   $  40,700  $  11,400
        Mutual funds                   259,900     249,400    (10,500)
                                    __________   _________  __________
                                    $  289,200   $ 290,100  $     900
                                    ==========   =========  ==========


5.	Inventories:

At interim reporting periods, inventories for financial statement purposes
are based on perpetual inventory records. Components of inventory are as
follows:

                        March 31,  		   June 30,
                          2017   		     2016
                      __________                   ___________
Raw Materials         $1,364,900		   $1,529,800
Work in process          429,500    		      425,300
Finished Goods           411,500		      457,000
                      __________                   __________
                      $2,205,900	           $2,412,100
                      ==========                   ==========
                                        9



6.	Earnings (Loss) per common share:

Basic earnings (loss) per common share are computed by dividing net
income (loss) by the weighted-average number of shares outstanding.
Diluted earnings (loss) per common share include the dilutive effect
of stock options, if any.



           Earnings (Loss) per common share was computed as follows:

                           For the Three Month	For the Nine Month
                           Periods Ended		Periods Ended
                           March 31,              	March 31,
                           ___________________  _____________________
    			      2017       2016  	     2017     2016
                           ___________________  _____________________
Net income (loss)           $ 65,600  ($ 36,900)  $ 62,200  ($  2,600)
                            ========  =========   ========  =========
Weighted average common
 shares outstanding        1,492,334  1,489,112  1,490,189  1,489,112
Effect of dilutive
 securities                       38       -         1,309       -
                           _________  _________  _________  _________
Weighted average dilutive
common shares outstanding  1,492,372  1,489,112  1,491,498  1,489,112
                           =========  =========  =========  =========
Basic earnings (loss) per
common share		    $  .04    ($  .02)     $  .04    ($  .00)
                            ======    =======      ======    =======
Diluted earnings (loss) per
common share 		    $  .04    ($  .02)     $  .04    ($  .00)
                            ======    =======      ======    =======

Approximately 33,500 and 38,500 shares of the Company's Common Stock
issuable upon the exercise of outstanding stock options were excluded
from the calculation of diluted earnings per common share for the three
and nine month periods ended March 31, 2017 and 2016, respectively,
because the effect would be anti-dilutive.

7.	Goodwill and Other Intangible Assets:

Goodwill represents the excess of the purchase price over the fair
value of the net assets acquired in connection with the Company's
acquisitions.  Goodwill amounted to $705,300 as of March 31, 2017
and June 30, 2016, respectively, all of which is deductible for
tax purposes.

The components of other intangible assets are as follows:


			  Useful                Accumulated
			  Lives         Cost    Amortization     Net
                         _________  __________  ____________ __________
 At March 31, 2017:

 Technology, trademarks  5/10 yrs. $  722,800   $  532,000   $  190,800
 Trade names		    6 yrs.    140,000	    71,900       68,100
 Websites		    5 yrs.    210,000	   129,500       80,500
 Customer relationships  9/10 yrs.    357,000	   278,100       78,900
 Sublicense agreements     10 yrs.    294,000	   158,000	136,000
 Non-compete agreements     5 yrs.    384,000	   280,500      103,500
 Intellectual property,
  research & development
  (IPR&D)		    3 yrs.     110,000	   110,000	   -
 Other intangible assets    5 yrs.     194,500     162,100       32,400
                                    __________  __________   __________
                                    $2,412,300  $1,722,100   $  690,200
                                    ==========  ==========   ==========


                                 10





			  Useful                Accumulated
			  Lives         Cost    Amortization     Net
                         _________  __________  ____________ __________
 At June 30, 2016:
 Technology, trademarks  5/10 yrs.  $  722,800  $  468,800   $  254,000
 Trade names                6 yrs.     140,000 	    54,400       85,600
 Websites                   5 yrs.     210,000      98,000      112,000
 Customer relationships  9/10 yrs.     357,000     261,600       95,400
 Sublicense agreements     10 yrs.     294,000     136,000      158,000
 Non-compete agreements     5 yrs.     384,000     239,100      144,900
 Intellectual Property,
 Research & Development
 (IPR&D)                    3 yrs.     110,000      85,500       24,500
 Other intangible assets    5 yrs.     177,900     154,700       23,200
                                    __________  __________   __________
	  			    $2,395,700  $1,498,100   $  897,600
                                    ==========  ==========   ==========


Total amortization expense was $69,900 and $89,400 for the three months
ended March 31, 2017 and 2016, respectively and $224,000 and $263,200
for the nine months ended March 31, 2017 and 2016, respectively.  As of
March 31, 2017, estimated future amortization expense related to
intangible assets is $73,400 for the remainder of the fiscal year
ending June 30, 2017, $288,500 for fiscal 2018, $210,600 for fiscal
2019, $45,100 for fiscal 2020, $43,500 for fiscal 2021, and $29,100
thereafter.





                                11




SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

Item 2. Management?s Discussion and Analysis or Plan of Operations

Certain statements contained in this report are not based on historical
facts, but are forward-looking statements that are based upon various
assumptions about future conditions.  Actual events in the future could
differ materially from those described in the forward-looking information.
Numerous unknown factors and future events could cause such differences,
including but not limited to, product demand, market acceptance, impact
of competition, the ability to reach final agreements, the ability to
finance and produce catalyst research instruments to customers'
satisfaction, adverse economic conditions, and other factors affecting
the Company's business that are beyond the Company's control.
Consequently, no forward-looking statement can be guaranteed.

We undertake no obligation to publicly update forward-looking statements,
whether as a result of new information, future events or otherwise.

Liquidity and Capital Resources

Cash and cash equivalents decreased $33,700 to $1,211,300 as of March 31,
2017 from $1,245,000 as of June 30, 2016.

Operating activities provided cash of $204,800 for the nine month period
ended March 31, 2017 as compared to the $214,900 used during the nine month
period ended March 31, 2016. The current year period reflected income from
operations and significantly lower amounts of work-in-progress inventories
for the Catalyst Research Instruments Operations related to a significant
order shipped last year, partially offset by higher amounts in accrued
expenses.  Net cash used in investing activities was $38,600 for the nine
months ended March 31, 2017 compared to $55,200 for the comparable period
last year primarily due to decreased capital expenditures in the current
year period.  Net cash used in financing activities was $199,900 for the
nine months ended March 31, 2017 compared to $869,100 provided by financing
activities in the comparable prior year period primarily due to the proceeds
from the export-related line of credit to finance the inventories discussed
above in the prior year period and higher contingent consideration paid.

The Company's working capital increased by $215,500 to $4,247,400 as of
March 31, 2017 from $4,031,900 at June 30, 2016.

The Company has two lines of credit through June 2017 with First National
Bank of Pennsylvania comprised of (i) an Export-Related Revolving Line of
Credit which is guaranteed by the Export-Import Bank of the United States
which provides for export-related borrowings of up to $200,000, bearing
interest at the prime rate plus 1% and an annual fee of 1.75% and (ii) a
second one-year Demand Line of Credit which provides for borrowings of up
to $300,000 for regular working capital needs, bearing interest at the
prime rate, currently 4.0%.  Advances on both lines are secured by a
pledge of the Company's assets including inventory, accounts, chattel
paper, equipment and general intangibles of the Company.  As of March
31, 2017 and June 30, 2016, the Company had no borrowings outstanding.

Management believes that the Company will be able to meet its cash flow
needs during the next 12 months from its available financial resources
which include its cash and investment securities, income from operations,
and the lines of credit which are expected to be renewed.


                                   12


Results of Operations


Financial Overview

The Company recorded income before income tax expense of $82,900 and a loss
before income tax benefit of $48,300 for the three month periods ended
March 31, 2017 and 2016, respectively; and income before income tax of
$78,200 and a loss before income tax benefit of $3,100 for the nine month
periods ended March 31, 2017 and 2016, respectively, primarily due to higher
sales and gross profit margins of benchtop laboratory equipment and higher
royalties earned by the Bioprocessing Systems Operations, partially offset
by increased losses by the Catalyst Research Instruments Operations due
principally to lower gross margins.  The results reflect non-cash amounts
for depreciation and amortization of $87,100 and $108,300 for the three
months ended March 31, 2017 and 2016, respectively, and $276,600 and
$319,100 for the nine months ended March 31, 2017 and 2016, respectively.

The Three Months Ended March 31, 2017 Compared With the Three Months Ended
March 31, 2016

Net revenues for the three months ended March 31, 2017 increased by
$236,600 (14.1%) to $1,910,900 from $1,674,300 for the three months ended
March 31, 2016, as a result of a $131,500 increase in sales of benchtop
laboratory equipment and $110,200 increase in royalties earned by the
Bioprocessing Systems Operations, partially offset by a decrease of $5,100
in catalyst research instruments sales.  Sales of the benchtop laboratory
equipment products generally are pursuant to many small purchase orders
from distributors, while catalyst research instruments are sold pursuant
to a small number of larger orders, typically averaging over $100,000
each, resulting in significant swings in revenues.  The backlog of orders
for catalyst research instruments was $431,200 at March 31, 2017 compared
to $3,027,000 as of March 31, 2016, all of which is anticipated to be
delivered by June 30, 2017.  Revenues derived by the Bioprocessing Systems
Operations pertain to royalties earned from sublicenses.

The gross profit percentage for the three months ended March 31, 2017 was
44.8% compared to 40.7% for the three months ended March 31, 2016,
reflecting increased margins for the Benchtop Laboratory Equipment and
lower gross margins for catalyst research instruments as a result of
sales mix.  All the revenues derived by the Bioprocessing Systems
Operations related to net royalties earned.

General and administrative expenses for the three months ended March 31,
2017 amounted to $435,100 compared to $426,700 for the three months ended
March 31, 2016.

Selling expenses for the three months ended March 31, 2017 increased
$27,700 (14.1%) to $223,900 compared to $196,200 for the three months
ended March 31, 2016 principally due to increased online marketing
activities by the Benchtop Laboratory Equipment Operations and trade
show activity by the Catalyst Research Instruments Operations.

                                 13







Research and development expenses for the three months ended March 31,
2017 increased $20,700 (22.2%) to $114,100 from $93,400 for the three
months ended March 31, 2016, primarily the result of increased new
product development expenses incurred by the Company's Bioprocessing
Systems Operations.

Total other income (expense), net for the three month period ended
March 31, 2017 was ($100) compared to ($13,200) for the three month
period ended March 31, 2016 due to decreased interest expense as a
result of less borrowings during the current period.

For the three months ended March 31, 2017, income tax expense was
$17,300 compared to tax benefit of $11,400 for the prior year
comparative period due to income for the current year period.

As a result, the net income for the three months ended March 31,
2017 was $65,600 compared to a loss of $36,900 for the three months
ended March 31, 2016.

The Nine Months Ended March 31, 2017 Compared With the Nine Months
Ended March 31, 2016

Net revenues for the nine months ended March 31, 2017 increased by
$1,006,900 (19.6%) to $6,153,800 compared to $5,146,900 for the
nine months ended December 31, 2015, due to increases of $697,100,
$208,500 and $101,300 in sales of catalyst research instruments,
benchtop laboratory equipment, and bioprocessing systems royalties,
respectively.

The gross profit percentage for the nine months ended March 31, 2017
decreased to 37.7% compared to 41.1% for the nine months ended March 31,
2016, reflecting lower gross margins for catalyst research instruments
as a result of sales mix and increased margins for the Benchtop
Laboratory Equipment.

All the revenues derived by the Bioprocessing Systems Operations
related to net royalties earned.

General and administrative expenses increased by $26,200 (2.1%) to
$1,256,700 for the nine months ended March 31, 2017 from $1,230,500
for the comparable period of the prior year, primarily due to
various expenses incurred by the Benchtop Laboratory Equipment
Operations.

Selling expenses for the nine months ended March 31, 2017 increased
by $74,400 (12.6%) to $664,800 from $590,400 for the nine months
ended March 31, 2016, principally due to online marketing activities
by the Benchtop Laboratory Equipment Operations and trade show
activity by the Catalyst Research Instruments Operations.

Research and development expenses for the nine months ended March
31,2017 increased by $71,500 (27.2%) to $334,500 compared to
$263,000 for the nine months ended March 31, 2016, primarily the
result of increased new product development by the Company's
Bioprocessing Systems Operations and the Benchtop Laboratory
Equipment Operations.

Total other income (expense), net, for the nine month period ended
March 31, 2017 increased to $13,600 from ($33,200) for the nine
months ended March 31, 2016 primarily due to decreased interest
expense.


                                 14




For the nine month period ended March 31, 2017, the income tax
expense was $16,000 compared to income tax benefit of $500 for the
comparable period of the prior fiscal year due to income during the
current year period.

As a result, net income for the nine months ended March 31, 2017 was
$62,200 compared to a net loss of $2,600 for the nine months ended
March 31, 2016.








                                  15






Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures.  As of the end
of the period covered by this report, based on an evaluation of the
Company's disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934),
the Chief Executive and Chief Financial Officer of the Company has
concluded that the Company's disclosure controls and procedures are
effective to ensure that information required to be disclosed by
the Company in its Exchange Act reports is recorded, processed,
summarized and reported within the applicable time periods specified
by the SEC's rules and forms. The Company also concluded that
information required to be disclosed in such reports is accumulated
and communicated to the Company's management, including its principal
executive and principal financial officer, as appropriate to allow
timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There was no
change in the Company's internal controls over financial reporting
that occurred during the most recently completed fiscal quarter
that materially affected or is reasonably likely to materially
affect the Company's internal controls over financial reporting.


Part II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K

	(a) Exhibit Number:	Description

31.1  Certification of Chief Executive Officer and Chief Financial
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification of Chief Executive Officer and Chief Financial
Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	(b) Reports on Form 8-K:

	Report dated February 10, 2017 reporting under Item 1.01.

	Report dated January 15, 2017 reporting under Item 8.01.
















                                  16



          SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES



                             SIGNATURE



In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.




                              Scientific Industries, Inc.
                              Registrant


                              /s/ Helena R. Santos
			      ____________________________
                              Helena R. Santos
                              President, Chief Executive Officer
                              and Treasurer
                              Principal Executive, Financial and
                              Accounting Officer

Date: May 12, 2017












                                17

EX-31

						Exhibit 32.1



                             CERTIFICATION

The undersigned as Chief Executive Officer and Chief Financial Officer
of the Company, does hereby certify that the foregoing Quarterly Report
of SCIENTIFIC INDUSTRIES, INC. (the "Company"), on Form 10-Q for the
period ended March 31, 2017:

	(1)	Fully complies with the requirements of Section 13 or
15 (d) of the Securities Exchange Act of 1934; and

	(2)	Fairly presents, in all material respects, the financial
condition and results of operations of the Company.





May 12, 2017


/s/ Helena R. Santos

____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer



A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to
the Securities and Exchange Commission or its staff upon request.

EX-32

          					Exhibit 31.1

                      CERTIFICATION

I, Helena R. Santos, certify that:

1.	I have reviewed this report on Form 10-Q for the quarter
ended March 31, 2017 of Scientific Industries, Inc., a smaller
reporting company (the "Registrant");

2.	Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the Registrant as of, and for, the periods presented in
this report;

4.	I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15 (f) and 15d-15(f) for the
Registrant and have:

a)	Designed such internal disclosure and procedures, or caused such
controls and procedures to be designed under my supervision, to ensure
that material information relating to the Registrant, including its
consolidated subsidiaries, is made known to me by others within those
entities, particularly during the period in which this report is being
prepared;

b)	Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed
under my supervision, to provide reasonable assurance, regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted
accounting principles;

c)	Evaluated the effectiveness of the Registrant's disclosure
controls and procedures and presented in this report my conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and

d)	Disclosed in this report any change in the Registrant's internal
control over financial reporting that occurred during the Registrant's
most recent fiscal quarter that has materially affected, or is
reasonably likely to affect, the Registrant?s internal control over
financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal
controls over financial reporting, to the Registrant's auditors and
the audit committee of the Registrant's board of directors (or persons
performing the equivalent functions):

a)	 All significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which
are reasonably likely to adversely affect the Registrant's ability to
record, process, summarize and report financial information; and

b)	 Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrant's
internal controls over financial reporting.

May 12, 2017


/s/ Helena R. Santos
____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer

XML

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2017	May 01, 2017
Document And Entity Information
Entity Registrant Name	SCIENTIFIC INDUSTRIES INC
Entity Central Index Key	0000087802
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,494,112
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Current Assets:
Cash and cash equivalents	$ 1,211,300	$ 1,245,000
Investment securities	294,000	290,100
Trade accounts receivable, net	1,327,700	1,231,900
Inventories	2,205,900	2,412,100
Prepaid expenses and other current assets	73,100	47,200
Deferred taxes	141,000	140,600
Total current assets	5,253,000	5,366,900
Property and equipment at cost, net	212,900	251,100
Intangible assets, net	690,200	897,600
Goodwill	705,300	705,300
Other assets	52,500	52,500
Deferred taxes	284,200	275,900
Total assets	7,198,000	7,549,300
Current Liabilities:
Accounts payable	343,100	342,400
Customer advances	107,900	0
Notes payable, current portion	6,600	6,400
Accrued expenses and taxes, current portion	532,000	849,700
Contingent consideration, current portion	16,000	136,500
Total current liabilities	1,005,600	1,335,000
Notes payable, less current portion	7,500	12,500
Accrued expenses, less current portion	60,000	60,000
Contingent consideration, less current portion	164,200	209,800
Total liabilities	1,237,300	1,617,300
Shareholders' equity:
Common stock, $.05 par value; authorized 7,000,000 shares; 1,513,914 and 1,508,914 issued and outstanding at March 31, 2017 and June 30, 2016	75,700	75,400
Additional paid-in capital	2,515,000	2,498,500
Accumulated other comprehensive income (loss)	(4,700)	900
Retained earnings	3,427,100	3,409,600
Total	6,013,100	5,984,400
Less common stock held in treasury, at cost, 19,802 shares	52,400	52,400
Total shareholders' equity	5,960,700	5,932,000
Total liabilities and shareholders' equity	$ 7,198,000	$ 7,549,300

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Shareholders' equity:
Common stock,par value	$ 0.05	$ 0.05
Common stock, authorized shares	7,000,000	7,000,000
Common stock, issued shares	1,513,914	1,508,914
Common stock, outstanding shares	1,513,914	1,508,914
Stock held in treasury, shares	19,802	19,802

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 1,910,900	$ 1,674,300	$ 6,153,800	$ 5,146,900
Cost of revenues	1,054,800	993,100	3,833,200	3,032,900
Gross profit	856,100	681,200	2,320,600	2,114,000
Operating Expenses:
General & administrative	435,100	426,700	1,256,700	1,230,500
Selling	223,900	196,200	664,800	590,400
Research & development	114,100	93,400	334,500	263,000
Total operating expenses	773,100	716,300	2,256,000	2,083,900
Income (loss) from operations	83,000	(35,100)	64,600	30,100
Other income (expense):
Investment income	1,100	300	10,100	5,700
Other	0	200	5,700	(3,000)
Interest expense	(1,200)	(13,700)	(2,200)	(35,900)
Total other income, (expense) net	(100)	(13,200)	13,600	(33,200)
Income (loss) before income taxes (benefit)	82,900	(48,300)	78,200	(3,100)
Income tax expense (benefit):
Current	38,900	2,200	23,400	43,100
Deferred	(21,600)	(13,600)	(7,400)	(43,600)
Total income tax expense (benefit)	17,300	(11,400)	16,000	(500)
Net income (loss)	$ 65,600	$ (36,900)	$ 62,200	$ (2,600)
Basic earnings (loss) per common share	$ .04	$ (.02)	$ .04	$ 0.00
Diluted earnings (loss) per common share	0.04	(0.02)	0.04	0.00
Cash dividends declared per common share	$ .03	$ 0.00	$ .03	$ 0.00

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements Of Comprehensive Income Loss
Net income (loss)	$ 65,600	$ (36,900)	$ 62,200	$ (2,600)
Other comprehensive income (loss):
Unrealized holding gain (loss) on investments arising during period, net of tax	1,300	3,000	(5,600)	(1,900)
Comprehensive income (loss)	$ 66,900	$ (33,900)	$ 56,600	$ (4,500)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net income (loss)	$ 62,200	$ (2,600)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Gain on sale of investments	(3,200)	0
Loss on asset disposal	0	2,700
Depreciation and amortization	276,500	319,100
Deferred income tax expense	(7,400)	(43,600)
Stock-based compensation	1,300	11,200
Changes in operating assets and liabilities:
Accounts receivable	(95,800)	364,600
Inventories	206,200	(1,461,200)
Prepaid expenses and other current assets	(25,900)	13,800
Accounts payable	700	194,700
Customer advances	107,900	191,400
Accrued expenses	(317,700)	195,000
Total adjustments	142,600	(212,300)
Net cash provided by (used in) operating activities	204,800	(214,900)
Investing activities:
Redemption of investment securities, available-for-sale	11,100	0
Purchase of investment securities, available-for-sale	(18,700)	(2,700)
Capital expenditures	(18,200)	(45,100)
Purchase of other intangible assets	(12,800)	(7,400)
Net cash used in investing activities	(38,600)	(55,200)
Financing activities:
Line of credit proceeds	250,000	970,000
Line of credit repayments	(250,000)	0
Cash dividend declared and paid	(44,500)	0
Payments of contingent consideration	(166,100)	(100,900)
Proceeds from exercise of stock options	15,500	0
Principal payments on note payable	(4,800)	0
Net cash provided by financing activities	(199,900)	869,100
Net increase (decrease) in cash and cash equivalents	(33,700)	599,000
Cash and cash equivalents, beginning of year	1,245,000	482,000
Cash and cash equivalents, end of period	1,211,300	1,081,000
Cash paid during the period for:
Income Taxes	213,500	35,500
Interest	$ 22,000	$ 27,200

XML

1. Summary of significant accounting policies

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of significant accounting policies

Principles of consolidation:

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc. (“Scientific”), a Delaware corporation, Altamira Instruments, Inc.(“Altamira”), a wholly-owned subsidiary and Delaware corporation, Scientific Packaging Industries, Inc. (an inactive wholly-owned subsidiary and New York corporation) and Scientific Bioprocessing, Inc. (“SBI”), a wholly-owned subsidiary and Delaware corporation. All are collectively referred to as the “Company”. All material intercompany balances and transactions have been eliminated.

XML

2. Recent Accounting Pronouncements

9 Months Ended

Mar. 31, 2017

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other, (Topic 350): Simplifying the Test for Goodwill Impairment, which is intended to simplify the subsequent measurement and impairment of goodwill. The ASU simplifies the complexity of evaluating goodwill for impairment by eliminating the second step of the impairment test, which compares the implied fair value of a reporting unit's goodwill to the carrying amount of that goodwill. Instead, the ASU requires entities to compare the fair value of a reporting unit to its carrying amount in order to determine the amount of goodwill impairment recognized. ASU No. 2017-04 is effective for fiscal years and interim periods within those years beginning after December 15, 2019. Early adoption of all the amendments for ASU 2017-04 is permitted. Amendments must be applied prospectively. The Company is in process of assessing the impact of the adoption of ASU No. 2017-04 on its financial position, results of operations and cash flows.

In February 2016, the FASB issued authoritative guidance that requires lessees to account for most leases on their balance sheets with the liability being equal to the present value of the lease payments.  The right-of-use asset will be based on the lease liability adjusted for certain costs such as direct costs.  Lease expense will be recognized similar to

current accounting guidance with operating leases resulting in a straight- line expense and financing leases resulting in a front-loaded expense similar to the current accounting for capital leases.  This guidance becomes effective for the Company’s fiscal 2020 first quarter, with early adoption permitted. 

This guidance must be adopted using a modified retrospective transition approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and provides for certain practical expedients.  The Company is currently evaluating the timing, impact and method of applying this guidance on its consolidated financial statements.

XML

3. Segment Information and Concentrations

9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors ("Benchtop Laboratory Equipment"), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis ("Catalyst Research Instruments") and the marketing and production of bioprocessing systems for laboratory research in the biotechnology industry sold directly to customers and through distributors ("Bioprocessing Systems").

Segment information is reported as follows (foreign sales are principally to customers in Europe and Asia):

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Three months ended March 31, 2017:
Revenues	$	1,410,800	$	359,800		$	140,300	$	—	$	1,910,900
Foreign Sales		611,400		37,100			—		—		648,500
Income (Loss) from Operations		88,900		(82,400	)		76,500		—		83,000
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		4,600		—			7,000		—		11,600
Depreciation and Amortization		73,500		1,600			12,000		—		87,100

		Benchtop Laboratory Equipment		Catalyst Research Instruments		Bioprocessing Systems			Corporate and Other			Consolidated
Three months ended March 31, 2016:
Revenues	$	1,279,300	$	364,900	$	30,100		$	—		$	1,674,300
Foreign Sales		597,300		25,900		—			—			623,200
Income (Loss) from Operations		2,800		5,500		(29,600	)		(13,800	)		(35,100	)
Assets		4,358,700		2,898,400		746,200			595,000			8,598,300
Long-Lived Asset Expenditures		31,500		3,200		3,700			—			38,400
Depreciation and Amortization		74,800		9,000		24,500			—			108,300

Approximately 54% and 50% of net sales of benchtop laboratory equipment for the three month periods ended March 31, 2017 and 2016, respectively, were derived from the Company's main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 21% and 22% of total benchtop laboratory equipment sales were derived from the Torbal Scales Division for the three months ended March 31, 2017 and 2016, respectively.

Two benchtop laboratory equipment customers accounted for approximately 15% and 19% of the segment's net sales for the three month periods ended March 31, 2017 and 2016 (11% and 15% of total revenues, respectively, for the periods).

Sales of catalyst research instruments are generally pursuant to large orders averaging more than $100,000 per order to a limited numbers of customers. Sales to two customers in the three months ended March 31, 2017 and two different customers in the three months ended March 31, 2016, accounted respectively for 76% and 86% of the segment's net sales for each of the periods (14% and 19% of total revenues, respectively, for the periods).

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Nine months ended March 31, 2017:
Revenues	$	4,334,400	$	1,629,400		$	190,000	$	—	$	6,153,800
Foreign Sales		1,924,400		52,200			—		—		1,976,600
Income (Loss) from Operations		252,900		(197,400	)		9,100		—		64,600
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		18,200		—			12,800		—		31,000
Depreciation and Amortization		226,800		12,700			37,000		—		276,500

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other			Consolidated
Nine months ended March 31, 2016:
Revenues	$	4,125,900	$	932,300		$	88,700		$	—		$	5,146,900
Foreign Sales		1,960,700		139,200			—			—			2,099,900
Income (Loss) from Operations		245,200		(86,700	)		(92,500	)		(35,900	)		30,100
Assets		4,358,700		2,898,400			746,200			595,000			8,598,300
Long-Lived Asset Expenditures		39,900		3,200			9,400			—			52,500
Depreciation and Amortization		222,800		22,900			73,400			—			319,100

Approximately 53% and 50% of net sales of benchtop laboratory equipment for the nine month periods ended March 31, 2017 and 2016,respectively, were derived from sales of the Company's main product, the Vortex-Genie 2 mixer, excluding accessories. 7 Approximately 23% and 21% of total benchtop laboratory equipment sales for the nine months ended March 31, 2017 and 2016, respectively, were derived from sales of the Torbal Scales Division.

Two benchtop laboratory equipment customers, accounted for approximately 11% and 15% of the segment's net sales (% and 12% of total revenues) for the nine month periods ended March 31, 2017 and 2016, respectively.

Sales of catalyst research instruments to four customers in the nine months ended March 31, 2017 and to four other customers in the nine months ended March 31, 2016 accounted for approximately 92% and 87% of that segment's net sales (24% and 16% of total revenues) for the respective nine month periods.

The Company's foreign sales are principally made to customers in Europe and Asia. The Company also has an arrangement with a supplier for annual minimum purchase commitments through February 2020 which the Company has already met for the current year.

XML

4. Fair Value of Financial Instruments

9 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements concerning fair value and establishes a fair value hierarchy of valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The following tables set forth by level within the fair value hierarchy the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2017 and June 30, 2016 according to the valuation techniques the Company used to determine their fair values:

	Fair Value Measurements Using Inputs Considered as
Assets:
	Fair Value at March 31, 2017		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,211,300	$	1,211,300	$	—	$	—
Available for sale securities		294,000		294,000		—		—
Total	$	1,505,300	$	1,505,300	$	—	$	—
Liabilities:
Contingent consideration	$	180,200	$	—	$	—	$	180,200

		Fair Value Measurements Using Inputs Considered as
Assets:
		Fair Value at June 30, 2016		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,245,000	$	1,245,000	$	—	$	—
Available for sale securities		290,100		290,100		—		—
Total	$	1,535,100	$	1,535,100	$	—	$	—
Liabilities:
Contingent consideration	$	346,300	$	—	$	—	$	346,300

The following table sets forth an analysis of changes during the nine months ended March 31, 2017, Level 3 financial liabilities of the Company:

Beginning balance, June 30, 2016	$	346,300
Payments		(166,100	)
Ending Balance, March 31, 2017	$	180,200

Investments in marketable securities classified as available-for-sale by security type at March 31, 2017 and June 30, 2016 consisted of the following:

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At March 31, 2017:
Available for sale:
Equity securities	$	37,000	$	49,500	$	12,500
Mutual funds		261,700		244,500		(17,200	)
	$	298,700	$	294,000	$	(4,700	)

		Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2016:
Available for sale:
Equity securities	$	29,300	$	40,700	$	11,400
Mutual funds		259,900		249,400		(10,500	)
	$	289,200	$	290,100	$	900

XML

5. Inventories

9 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

At interim reporting periods, inventories for financial statement purposes are based on perpetual inventory records. Components of inventory are as follows:

	March 31, 2017		June 30, 2016
Raw materials	$	1,364,900	$	1,529,800
Work in process		429,500		425,300
Finished goods		411,500		457,000
	$	2,205,900	$	2,412,100

XML

6. Earnings (Loss) per common share

9 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Earnings (Loss) per common share

Basic earnings (loss) per common share are computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings (loss) per common share include the dilutive effect of stock options, if any.

Earnings (Loss) per common share was computed as follows:

	For the Three Month Periods Ended March 31,					For the Nine Month Periods Ended March 31
	2017		2016			2017		2016
Net income (loss)	$	65,600	$	(36,900	)	$	62,200	$	(2,600	)
Weighted average common shares outstanding		1,492,334		1,489,112			1,490,189		1,489,112
Dilutive securities		38		—			1,309		—
Weighted average dilutive common shares outstanding		1,492,372		1,489,112			1,491,498		1,489,112
Basic earnings (loss) per common share	$	0.04	$	(0.02	)	$	0.04	$	0.00
Diluted earnings (loss) per common share	$	0.04	$	(0.02	)	$	0.04	$	0.00

Approximately 33,500 and 38,500 shares of the Company's Common Stock issuable upon the exercise of outstanding stock options were excluded from the calculation of diluted earnings per common share for the three and nine month periods ended March 31, 2017 and 2016, respectively, because the effect would be anti-dilutive.

XML

7. Goodwill and Other Intangible Assets

9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company's acquisitions. Goodwill amounted to $705,300 as of March 31, 2017 and June 30, 2016, respectively, all of which is deductible for tax purposes.

The components of other intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
At March 31, 2017:
Technology, trademarks	5/10 yrs.	$	722,800	$	532,000	$	190,800
Trade names	6 yrs.		140,000		71,900		68,100
Websites	5 yrs.		210,000		129,500		80,500
Customer relationships	9/10 yrs.		357,000		278,100		78,900
Sublicense agreements	10 yrs.		294,000		158,000		136,000
Non-compete agreements	5 yrs.		384,000		280,500		103,500
Intellectual property,Reasearch & Development (IPR&D)	3 yrs.		110,000		110,000		0
Other intangible assets	5 yrs.		194,500		162,100		32,400
		$	2,412,300	$	1,722,100	$	690,200

	Useful Lives		Cost		Accumulated Amortization		Net
At June 30, 2016:
Technology,  trademarks	5/10 yrs.	$	722,800	$	468,800	$	254,000
Trade names	6 yrs.		140,000		54,400		85,600
Websites	5 yrs.		210,000		98,000		112,000
Customer relationships	9/10 yrs.		357,000		261,600		95,400
Sublicense agreements	10 yrs.		294,000		136,000		158,000
Non-compete agreements	5 yrs.		384,000		239,100		144,900
Intellectual property,Reasearch & Development (IPR&D)	3 yrs.		110,000		85,500		24,500
Other intangible assets	5 yrs.		177,900		154,700		23,200
		$	2,395,700	$	1,498,100	$	897,600

Total amortization expense was $69,900 and $89,400 for the three months ended March 31, 2017 and 2016, respectively and $224,000 and $263,200 for the nine months ended March 31, 2017 and 2016, respectively. As of March 31, 2017, estimated future amortization expense related to intangible assets is $73,400 for the remainder of the fiscal year ending June 30, 2017, $288,500 for fiscal 2018, $210,600 for fiscal 2019, $45,100 for fiscal 2020, $43,500 for fiscal 2021, and $29,100 thereafter.

XML

1. Summary of significant accounting policies (Policies)

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Principles of consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc. (“Scientific”), a Delaware corporation, Altamira Instruments, Inc.(“Altamira”), a wholly-owned subsidiary and Delaware corporation, Scientific Packaging Industries, Inc. (an inactive wholly-owned subsidiary and New York corporation) and Scientific Bioprocessing, Inc. (“SBI”), a wholly-owned subsidiary and Delaware corporation. All are collectively referred to as the “Company”. All material intercompany balances and transactions have been eliminated.

New Accounting Pronouncements

In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other, (Topic 350): Simplifying the Test for Goodwill Impairment, which is intended to simplify the subsequent measurement and impairment of goodwill. The ASU simplifies the complexity of evaluating goodwill for impairment by eliminating the second step of the impairment test, which compares the implied fair value of a reporting unit's goodwill to the carrying amount of that goodwill. Instead, the ASU requires entities to compare the fair value of a reporting unit to its carrying amount in order to determine the amount of goodwill impairment recognized. ASU No. 2017-04 is effective for fiscal years and interim periods within those years beginning after December 15, 2019. Early adoption of all the amendments for ASU 2017-04 is permitted. Amendments must be applied prospectively. The Company is in process of assessing the impact of the adoption of ASU No. 2017-04 on its financial position, results of operations and cash flows.

In February 2016, the FASB issued authoritative guidance that requires lessees to account for most leases on their balance sheets with the liability being equal to the present value of the lease payments.  The right-of-use asset will be based on the lease liability adjusted for certain costs such as direct costs.  Lease expense will be recognized similar to

current accounting guidance with operating leases resulting in a straight- line expense and financing leases resulting in a front-loaded expense similar to the current accounting for capital leases.  This guidance becomes effective for the Company’s fiscal 2020 first quarter, with early adoption permitted. 

This guidance must be adopted using a modified retrospective transition approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and provides for certain practical expedients.  The Company is currently evaluating the timing, impact and method of applying this guidance on its consolidated financial statements.

XML

3. Segment Information and Concentrations (Tables)

9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Information

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Three months ended March 31, 2017:
Revenues	$	1,410,800	$	359,800		$	140,300	$	—	$	1,910,900
Foreign Sales		611,400		37,100			—		—		648,500
Income (Loss) from Operations		88,900		(82,400	)		76,500		—		83,000
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		4,600		—			7,000		—		11,600
Depreciation and Amortization		73,500		1,600			12,000		—		87,100

		Benchtop Laboratory Equipment		Catalyst Research Instruments		Bioprocessing Systems			Corporate and Other			Consolidated
Three months ended March 31, 2016:
Revenues	$	1,279,300	$	364,900	$	30,100		$	—		$	1,674,300
Foreign Sales		597,300		25,900		—			—			623,200
Income (Loss) from Operations		2,800		5,500		(29,600	)		(13,800	)		(35,100	)
Assets		4,358,700		2,898,400		746,200			595,000			8,598,300
Long-Lived Asset Expenditures		31,500		3,200		3,700			—			38,400
Depreciation and Amortization		74,800		9,000		24,500			—			108,300

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Nine months ended March 31, 2017:
Revenues	$	4,334,400	$	1,629,400		$	190,000	$	—	$	6,153,800
Foreign Sales		1,924,400		52,200			—		—		1,976,600
Income (Loss) from Operations		252,900		(197,400	)		9,100		—		64,600
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		18,200		—			12,800		—		31,000
Depreciation and Amortization		226,800		12,700			37,000		—		276,500

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other			Consolidated
Nine months ended March 31, 2016:
Revenues	$	4,125,900	$	932,300		$	88,700		$	—		$	5,146,900
Foreign Sales		1,960,700		139,200			—			—			2,099,900
Income (Loss) from Operations		245,200		(86,700	)		(92,500	)		(35,900	)		30,100
Assets		4,358,700		2,898,400			746,200			595,000			8,598,300
Long-Lived Asset Expenditures		39,900		3,200			9,400			—			52,500
Depreciation and Amortization		222,800		22,900			73,400			—			319,100

XML

4. Fair Value of Financial Instruments (Tables)

9 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Inputs

	Fair Value Measurements Using Inputs Considered as
Assets:
	Fair Value at March 31, 2017		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,211,300	$	1,211,300	$	—	$	—
Available for sale securities		294,000		294,000		—		—
Total	$	1,505,300	$	1,505,300	$	—	$	—
Liabilities:
Contingent consideration	$	180,200	$	—	$	—	$	180,200

		Fair Value Measurements Using Inputs Considered as
Assets:
		Fair Value at June 30, 2016		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,245,000	$	1,245,000	$	—	$	—
Available for sale securities		290,100		290,100		—		—
Total	$	1,535,100	$	1,535,100	$	—	$	—
Liabilities:
Contingent consideration	$	346,300	$	—	$	—	$	346,300

Changes to Level 3 Financial Liabilities

Beginning balance, June 30, 2016	$	346,300
Payments		(166,100	)
Ending Balance, March 31, 2017	$	180,200

Investments in Marketable Securitites

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At March 31, 2017:
Available for sale:
Equity securities	$	37,000	$	49,500	$	12,500
Mutual funds		261,700		244,500		(17,200	)
	$	298,700	$	294,000	$	(4,700	)

		Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2016:
Available for sale:
Equity securities	$	29,300	$	40,700	$	11,400
Mutual funds		259,900		249,400		(10,500	)
	$	289,200	$	290,100	$	900

XML

5. Inventories (Tables)

9 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

	March 31, 2017		June 30, 2016
Raw materials	$	1,364,900	$	1,529,800
Work in process		429,500		425,300
Finished goods		411,500		457,000
	$	2,205,900	$	2,412,100

XML

6. Earnings (Loss) per common share (Tables)

9 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Earnings per common share

	For the Three Month Periods Ended March 31,					For the Nine Month Periods Ended March 31
	2017		2016			2017		2016
Net income (loss)	$	65,600	$	(36,900	)	$	62,200	$	(2,600	)
Weighted average common shares outstanding		1,492,334		1,489,112			1,490,189		1,489,112
Dilutive securities		38		—			1,309		—
Weighted average dilutive common shares outstanding		1,492,372		1,489,112			1,491,498		1,489,112
Basic earnings (loss) per common share	$	0.04	$	(0.02	)	$	0.04	$	0.00
Diluted earnings (loss) per common share	$	0.04	$	(0.02	)	$	0.04	$	0.00

XML

7. Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

	Useful Lives	Cost		Accumulated Amortization		Net
At March 31, 2017:
Technology, trademarks	5/10 yrs.	$	722,800	$	532,000	$	190,800
Trade names	6 yrs.		140,000		71,900		68,100
Websites	5 yrs.		210,000		129,500		80,500
Customer relationships	9/10 yrs.		357,000		278,100		78,900
Sublicense agreements	10 yrs.		294,000		158,000		136,000
Non-compete agreements	5 yrs.		384,000		280,500		103,500
Intellectual property,Reasearch & Development (IPR&D)	3 yrs.		110,000		110,000		0
Other intangible assets	5 yrs.		194,500		162,100		32,400
		$	2,412,300	$	1,722,100	$	690,200

	Useful Lives		Cost		Accumulated Amortization		Net
At June 30, 2016:
Technology,  trademarks	5/10 yrs.	$	722,800	$	468,800	$	254,000
Trade names	6 yrs.		140,000		54,400		85,600
Websites	5 yrs.		210,000		98,000		112,000
Customer relationships	9/10 yrs.		357,000		261,600		95,400
Sublicense agreements	10 yrs.		294,000		136,000		158,000
Non-compete agreements	5 yrs.		384,000		239,100		144,900
Intellectual property,Reasearch & Development (IPR&D)	3 yrs.		110,000		85,500		24,500
Other intangible assets	5 yrs.		177,900		154,700		23,200
		$	2,395,700	$	1,498,100	$	897,600

XML

3. Segment Information and Concentrations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Depreciation and Amortization			$ 276,500	$ 319,100
Benchtop Laboratory Equipment [Member]
Revenues	$ 1,410,800	$ 1,279,300	4,334,400	4,125,900
Foreign Sales	611,400	597,300	1,924,400	1,960,700
Income (Loss) from Operations	88,900	2,800	252,900	245,200
Assets	4,170,900	4,358,700	4,170,900	4,358,700
Long-lived Asset Expenditures	4,600	31,500	18,200	39,900
Depreciation and Amortization	73,500	74,800	226,800	222,800
Catalyst Research Instruments [Member]
Revenues	359,800	364,900	1,629,400	932,300
Foreign Sales	37,100	25,900	52,200	139,200
Income (Loss) from Operations	(82,400)	5,500	(197,400)	(86,700)
Assets	1,822,200	2,898,400	1,822,200	2,898,400
Long-lived Asset Expenditures	0	3,200	0	3,200
Depreciation and Amortization	1,600	9,000	12,700	22,900
Bioprocessing Systems [Member]
Revenues	140,300	30,100	190,000	88,700
Foreign Sales	0	0	0	0
Income (Loss) from Operations	76,500	(29,600)	9,100	(92,500)
Assets	485,700	746,200	485,700	746,200
Long-lived Asset Expenditures	7,000	3,700	12,800	9,400
Depreciation and Amortization	12,000	24,500	37,000	73,400
Corporate and Other [Member]
Revenues	0	0	0	0
Foreign Sales	0	0	0	0
Income (Loss) from Operations	0	(13,800)	0	(35,900)
Assets	719,200	595,000	719,200	595,000
Long-lived Asset Expenditures	0	0	0	0
Depreciation and Amortization	0	0	0	0
Consolidated [Member]
Revenues	1,910,900	1,674,300	6,153,800	5,146,900
Foreign Sales	648,500	623,200	1,976,600	2,099,900
Income (Loss) from Operations	83,000	(35,100)	64,600	30,100
Assets	7,198,000	8,598,300	7,198,000	8,598,300
Long-lived Asset Expenditures	11,600	38,400	31,000	52,500
Depreciation and Amortization	$ 87,100	$ 108,300	$ 276,500	$ 319,100

XML

3. Segment Information and Concentrations (Details Narrative)	3 Months Ended			9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2017	Mar. 31, 2016
Benchtop Laboratory Equipment [Member]
Net sales	54.00%	50.00%		53.00%	50.00%
Benchtop Laboratory Equipment [Member] | TwoCustomers [Member]
Net sales	15.00%	19.00%		11.00%	15.00%
Total revenues	15.00%				12.00%
Benchtop Laboratory Equipment [Member] | Torbal Brand Products
Net sales	21.00%	22.00%		23.00%	21.00%
Total revenues		11.00%
Catalyst Research Instruments [Member]
Net sales	76.00%		86.00%	92.00%	87.00%
Total revenues	14.00%		19.00%	24.00%	16.00%

XML

4. Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015
Assets:
Cash and cash equivalents	$ 1,211,300	$ 1,245,000	$ 1,081,000	$ 482,000
Available for sale securities	294,000	290,100
Total	1,505,300	1,535,100
Liabilities:
Contingent consideration	180,200	346,300
Level 1
Assets:
Cash and cash equivalents	1,211,300	1,245,000
Available for sale securities	294,000	290,100
Total	1,505,300	1,535,100
Liabilities:
Contingent consideration	0	0
Level 2
Assets:
Cash and cash equivalents	0	0
Available for sale securities	0	0
Total	0	0
Liabilities:
Contingent consideration	0	0
Level 3
Assets:
Cash and cash equivalents	0	0
Available for sale securities	0	0
Total	0	0
Liabilities:
Contingent consideration	$ 180,200	$ 346,300

XML

4. Fair Value of Financial Instruments (Details 1)	Mar. 31, 2017 USD ($)
Fair Value Of Financial Instruments Details 1
Beginning balance	$ 346,300
Payments	(166,100)
Ending balance	$ 180,200

XML

4. Fair Value of Financial Instruments (Details 2) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Cost	$ 298,700	$ 289,200
Fair Value	294,000	290,100
Unrealized Holding Gain (Loss)	(4,700)	900
Equity Securities
Cost	37,000	29,300
Fair Value	49,500	40,700
Unrealized Holding Gain (Loss)	12,500	11,400
Mutual Funds
Cost	261,700	259,900
Fair Value	244,500	249,400
Unrealized Holding Gain (Loss)	$ (17,200)	$ (10,500)

XML

5. Inventories (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Inventory Disclosure [Abstract]
Raw Materials	$ 1,364,900	$ 1,529,800
Work in process	429,500	425,300
Finished Goods	411,500	457,000
Inventory	$ 2,205,900	$ 2,412,100

XML

6. Earnings (Loss) per common share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Net income (loss)	$ 65,600	$ (36,900)	$ 62,200	$ (2,600)
Weighted average common shares outstanding	1,492,334	1,489,112	1,490,189	1,489,112
Dilutive securities	38	0	1,309	0
Weighted average dilutive common shares outstanding	1,492,372	1,489,112	1,491,498	1,489,112
Basic earnings (loss) per common share	$ .04	$ (.02)	$ .04	$ 0.00
Diluted earnings (loss) per common share	$ 0.04	$ (0.02)	$ 0.04	$ 0.00

XML

6. Earnings (Loss) per common share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Common stock issuable upon the exercise of outstanding stock options	33,500	33,500	38,500	38,500

XML

7. Goodwill and Other Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Cost	$ 2,412,300	$ 2,395,700
Accumulated Amortization	1,722,100	1,498,100
Net	$ 690,200	$ 897,600
Technology, trademarks [Member]
Useful Lives Minimum	5 years	5 years
Useful Lives Maximum	10 years	10 years
Cost	$ 722,800	$ 722,800
Accumulated Amortization	532,000	468,800
Net	$ 190,800	$ 254,000
Trade names [Member]
Useful Lives	6 years	6 years
Cost	$ 140,000	$ 140,000
Accumulated Amortization	71,900	54,400
Net	$ 68,100	$ 85,600
Websites [Member]
Useful Lives	5 years	5 years
Cost	$ 210,000	$ 210,000
Accumulated Amortization	129,500	98,000
Net	$ 80,500	$ 112,000
Customer relationships [Member]
Useful Lives Minimum	9 years	9 years
Useful Lives Maximum	10 years	10 years
Cost	$ 357,000	$ 357,000
Accumulated Amortization	278,100	261,600
Net	$ 78,900	$ 95,400
Sublicense agreements [Member]
Useful Lives	10 years	10 years
Cost	$ 294,000	$ 294,000
Accumulated Amortization	158,000	136,000
Net	$ 136,000	$ 158,000
Non-compete agreements [Member]
Useful Lives	5 years	5 years
Cost	$ 384,000	$ 384,000
Accumulated Amortization	280,500	239,100
Net	$ 103,500	$ 144,900
Intellectual property, research & development (IPR&D) [Member]
Useful Lives	3 years	3 years
Cost	$ 110,000	$ 110,000
Accumulated Amortization	110,000	85,500
Net	$ 0	$ 24,500
Other intangible assets [Member]
Useful Lives	5 years	5 years
Cost	$ 194,500	$ 177,900
Accumulated Amortization	162,100	154,700
Net	$ 32,400	$ 23,200

XML

7. Goodwill and Other Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Estimated future amortization expense 2017	$ 73,400		$ 73,400
Estimated future amortization expense 2018	288,500		288,500
Estimated future amortization expense 2019	210,600		210,600
Estimated future amortization expense 2020	45,100		45,100
Estimated future amortization expense 2021	43,500		43,500
Estimated future amortization expense thereafter	29,100		29,100
Total amortization expense	69,900	$ 89,400	224,000	$ 26,300
Goodwill	$ 705,300		$ 705,300		$ 705,300